Document:

EX-10.13

 Exhibit 10.13 

EMPLOYMENT AGREEMENT 

This Employment Agreement (“Agreement”) is made effective as of May 2, 2016
(“Effective Date”), by and between ChemoCentryx, Inc., a Delaware corporation (the “Company”), and Rajinder Singh, D.Phil. (“Executive”).
 
 WHEREAS, the Company desires to employ Executive and Executive desires to commence employment with the Company on
the terms and conditions set forth below. 
 The parties agree as follows: 

1.           Definitions. For purposes of this Agreement, the
following terms shall have the following meanings: 

(a)          “Board’’ shall mean
the Board of Directors of the Company. 

(b)          “California WARN Act”
means California Labor Code Sections 1400 et seq. 

(c)          “Cause” shall mean that,
in the reasonable determination of the Company, Executive: 

(i)          has committed an act of fraud, embezzlement or dishonesty in
connection with Executive’s employment, or has intentionally committed some other illegal act that has, or may be reasonably expected to have, a material adverse impact on the Company or any successor or parent or subsidiary thereof; 

(ii)          has been convicted of, or entered a plea of
“guilty” or “no contest” to, a felony, or to any crime involving moral turpitude, which causes or may reasonably be expected to cause substantial economic injury to or substantial injury to the reputation of the Company or any
successor or parent or subsidiary thereof; 
 (iii)          has made any
unauthorized use or disclosure of confidential information or trade secrets of the Company or any successor or parent or subsidiary thereof that has, or may reasonably be expected to have, a material adverse impact on any such entity; 

(iv)          has materially breached a Company policy, materially breached
the provisions of this Agreement, or has committed any other intentional misconduct that has, or may be reasonably expected to have, a material adverse impact on the Company or any successor or parent or subsidiary thereof, or 

(v)          has intentionally refused or intentionally failed to act in
accordance with any lawful and proper direction or order of the Board or the appropriate individual to whom Executive reports; provided such direction is not materially inconsistent with Executive’s customary duties and responsibilities. 

(d)          “Change in Control”
shall mean and include each of the following: 
 (i)          the
acquisition, directly or indirectly, by any “person” or “group” (as those terms are defined in Sections 3(a)(9), 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended, and the rules thereunder) of “beneficial
ownership” (as determined pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, as amended) of securities entitled to vote generally in the election of directors (“voting
securities”) of the Company that represent fifty percent (50%) or more of the combined voting power of the Company’s then outstanding voting securities, other than: 

 (A)        an acquisition by a trustee
or other fiduciary holding securities under any employee benefit plan (or related trust) sponsored or maintained by the Company or any person controlled by the Company or by any employee benefit plan (or related trust) sponsored or maintained by the
Company or any person controlled by the Company, 
 (B)        an acquisition of
voting securities by the Company or a corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of the stock of the Company, 

(C)        an acquisition of voting securities pursuant to a transaction described in
subsection (ii) below that would not be a Change in Control under subsection (ii), or 

(D)        an acquisition of voting securities pursuant to the Company’s initial
public offering of its common stock; 
 Notwithstanding the foregoing, the following event shall not constitute an
“acquisition” by any person or group for purposes of this Section: an acquisition of the Company’s securities by the Company that causes the Company’s voting securities beneficially owned by a person or group to represent fifty
percent (50%) or more of the combined voting power of the Company’s then outstanding voting securities; provided, however, that if a person or group shall become the beneficial owner of fifty percent (50%) or more of the combined voting
power of the Company’s then outstanding voting securities by reason of share acquisitions by the Company as described above and shall, after such share acquisitions by the Company, become the beneficial owner of any additional voting securities
of the Company, then such acquisition shall constitute a Change in Control; or 

(ii)          The consummation by the Company (whether directly involving
the Company or indirectly involving the Company through one or more intermediaries) of (x) a merger, consolidation, reorganization, or business combination or (y) a sale or other disposition of all or substantially all of the
Company’s assets in any single transaction or series of related transactions or (z) the acquisition of assets or stock of another entity, in each case other than a transaction: 

(A)            Which results in the Company’s voting
securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or
indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company’s assets or otherwise succeeds to the business of the Company (the Company or such person, the “Successor
Entity”)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity’s outstanding voting securities immediately after the transaction, and 

(B)            After which no person or group beneficially owns
voting securities representing fifty percent (50%) or more of the combined voting power of the Successor Entity; provided, however, that no person or group shall be treated for purposes of this Section 1(d)(iii)(B) as beneficially owning
fifty percent (50%) or more of combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the consummation of the transaction; or 

(iii)        The Company’s stockholders approve a liquidation or dissolution of
the Company 
 For purposes of subsection (i) above, the calculation of voting power shall be made as if the date of
the acquisition were a record date for a vote of the Company’s stockholders, and for purposes of subsection (ii) above, the calculation of voting power shall be made as if the date of the consummation of the transaction were a record date
for a vote of the Company’s stockholders. 

  
 2 

 Notwithstanding the foregoing, a transaction shall not constitute a Change in
Control if it is a transaction effected primarily for the purpose of financing the Company with cash (as determined by the Board in its discretion and without regard to whether such transaction is effectuated by a merger, equity financing or
otherwise). The Board shall have full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change in Control of the Company has occurred pursuant to the above definition, and the date of the occurrence
of such Change in Control and any incidental matters thereto. 

(e)          “Code” shall mean the
Internal Revenue Code of 1986, as amended. 

(f)          “Good Reason” shall mean
the occurrence of any of the following events or conditions without Executive’s written consent: 

(i)            a material diminution in Executive’s
authority, duties or responsibilities; 
 (ii)           a material
diminution in the authority, duties or responsibilities of the supervisor to whom Executive is required to report; 

(iii)          a material diminution in Executive’s base compensation,
unless such a reduction is imposed across-the-board to senior management of the Company; 

(iv)          a material change in the geographic location at which
Executive must perform his or her duties (and the Company and Executive agree that any involuntary relocation of Executive’s principal place of business to a location more than forty (40) miles in any direction from the Company’s
headquarters in Mountain View, California as of the Effective Date would constitute a material change); or 

(v)           any other action or inaction that constitutes a material
breach by the Company or any successor or affiliate of its obligations to Executive under this Agreement. 
 Executive must
provide written notice to the Company of the occurrence of any of the foregoing events or conditions without Executive’s written consent within ninety (90) days of the occurrence of such event. The Company or any successor or affiliate
shall have a period of thirty (30) days to cure such event or condition after receipt of written notice of such event from Executive. 

(g)          “Involuntary Termination”
means (i) Executive’s Separation from Service by reason of a termination of employment by the Company other than for Cause, death, or disability, or (ii) Executive’s Separation from Service by reason of resignation of employment
with the Company for Good Reason. Executive’s Separation from Service by reason of resignation from employment with the Company for Good Reason shall be an “Involuntary Termination” only if such Separation from Service also occurs
within six (6) months following the initial existence of the act or failure to act constituting Good Reason. In no event shall expiration of the Term constitute an Involuntary Termination. 

(h)          “Separation from Service”,
with respect to Executive means Executive’s “separation from service,” as defined in Treasury Regulation Section 1.409A-l(h). 

(i)          “Stock Awards” means all
stock options, restricted stock and such other awards granted pursuant to the Company’s stock option and equity incentive award plans or agreements and any shares of stock issued upon exercise thereof. 

  
 3 

(j)          “WARN Act” shall mean the
Worker Adjustment and Retraining Notification Act, 29 U.S.C. Sections 2101 et seq., and the Department of Labor regulations thereunder. 

2.          Term. The term of this Agreement (the
“Term”) shall commence on the Effective Date and shall continue in effect until December 31, 2016 (the “initial Termination Date”); provided, however,
that this Agreement shall be automatically extended for one (1) additional year on the Initial Termination Date and on each subsequent anniversary of the Initial Termination Date, unless the Company elects not to so extend the term of the
Agreement by notifying Executive, in writing, of such election not less than sixty (60) days prior to the last day of the Term as then in effect. 

3.          Services to Be Rendered. 

(a)          Duties and Responsibilities. Executive shall serve as
Senior Vice President, Research of the Company. In the performance of such duties, Executive shall report directly to the President and Chief Executive Officer of the Company (“CEO”) and shall be
subject to the direction of the Board and the CEO and to such limits upon Executive’s authority as the Board and the CEO may from time to time impose. Any change in Executive’s role without his or her consent such that he or she no longer
reports directly to the CEO shall constitute a material breach of this Agreement by the Company. Executive hereby consents to serve as an officer and/or director of the Company or any subsidiary or affiliate thereof without any additional salary or
compensation, if so requested by the CEO. Executive shall be employed by the Company on a full time basis. Executive’s primary place of work shall be the Company’s facility in Mountain View, California, or such other location within Santa
Clara County as may be designated by the CEO from time to time. Executive shall also render services at such other places within or outside the United States as the CEO may direct from time to time. Executive shall be subject to and comply with the
policies and procedures generally applicable to senior executives of the Company to the extent the same are not inconsistent with any term of this Agreement. 

(b)          Exclusive Services. Executive shall at all times
faithfully, industriously and to the best of his or her ability, experience and talent perform to the satisfaction of the Board and the CEO all of the duties that may be assigned to Executive hereunder and shall devote substantially all of his or
her productive time and efforts to the performance of such duties. Subject to the terms of the Employee Proprietary Information and Inventions Agreement referred to in Section 6(b), this shall not preclude Executive from devoting time to
personal and family investments or serving on community and civic boards, or participating in industry associations, provided such activities do not interfere with his or her duties to the Company, as determined in good faith by the Board or the
CEO. Executive agrees that he will not join any boards, other than community and civic boards (which do not interfere with his or her duties to the Company), without the prior approval of the Board or the CEO. 

4.          Compensation and Benefits. The Company shall pay or
provide, as the case may be, to Executive the compensation and other benefits and rights set forth in this Section 4. 

(a)          Base Salary. The Company shall pay to Executive a base
salary of $360,000 per year, payable in accordance with the Company’s usual pay practices (and in any event no less frequently than monthly). Executive’s base salary shall be subject to review annually by and at the sole discretion of the
Compensation Committee of the Board. 
 (b)          Bonus.
Executive shall participate in such incentive compensation plan as may be approved by the Compensation Committee of the Board from time to time for senior executives of the Company. Executive’s target bonus award under such plan shall be
thirty-five percent (35%) of Executive’s base salary. Any material reduction of Executive’s target bonus shall be considered a material breach of this Agreement by the Company. 

  
 4 

 (c)          Benefits.
Executive shall be entitled to participate in benefits under the Company’s benefit plans and arrangement, including, without limitation, any employee benefit plan or arrangement made available in the future by the Company to its senior
executives, subject to and on a basis consistent with the terms, conditions and overall administration of such plans and arrangements. The Company shall have the right to amend or delete any such benefit plan or an arrangement made available by the
Company to its senior executives and not otherwise specifically provided for herein. Any reduction of Executive’s benefits such that Executive’s benefits are, in the aggregate, materially less favorable to Executive than those benefits
offered to Executive as of the Effective Date shall be considered a material breach of this Agreement by the Company. 

(d)          Expenses. The Company shall reimburse Executive for
reasonable out-of-pocket business expenses incurred in connection with the performance of his or her duties hereunder, subject to (i) such policies as the Company
may from time to time establish, and (ii) Executive furnishing the Company with evidence in the form of receipts satisfactory to the Company substantiating the claimed expenditures. 

(e)          Paid Vacation. Executive shall be entitled to such
periods of paid vacation each year as provided from time to time under the Company’s vacation policy and as otherwise provided for senior executive officers; provided that Executive shall be entitled to earn at least three (3) weeks
of paid vacation per year. 
 (f)          Equity Awards.
Executive shall be entitled to participate in any equity or other employee benefit plan that is generally available to senior executive officers, as distinguished from general management, of the Company. Except as otherwise provided in this
Agreement, Executive’s participation in and benefits under any such plan shall be on the terms and subject to the conditions specified in the governing document of the particular plan. Subject to and following approval by the Company’s
Board of Directors (the “Board”), the Company shall grant you an option to purchase 180,000 shares of the Company’s common stock at its fair market value as determined by the Board as of the date of grant (the
“Option”) pursuant to the Company’s 2012 equity incentive plan (the “Plan”). The Option will be governed in full by the terms and conditions of the Plan and your individual grant agreement, including the
vesting schedule and requirements set forth therein. 

5.          Termination and Severance. Executive shall be entitled to
receive benefits upon termination of employment only as set forth in this Section 5: 

(a)          At-Will Employment: Termination. The Company and
Executive acknowledge that Executive’s employment is and shall continue to be at-will, as defined under applicable law, and that Executive’s employment with the Company may be terminated by either
party at any time for any or no reason, with or without notice. If Executive’s employment terminates for any reason, Executive shall not be entitled to any payments, benefits, damages, awards or compensation other than as provided in this
Agreement. Executive’s employment under this Agreement shall be terminated immediately on the death of Executive. 

(b)          Severance Upon Involuntary Termination Prior to a Change in
Control or More than 12 Months Following a Change in Control. If Executive’s employment is Involuntarily Terminated prior to a Change in Control or more than twelve (12) months following a Change in Control, Executive shall be entitled
to receive, in lieu of any severance benefits to which Executive may otherwise be entitled under any severance plan or program of the Company, the benefits provided below, which, with respect to clause (ii) below, will be payable in a lump sum
within ten (10) days following the effective date of Executive’s Release, but in no event later than two and one-half (2 1/2) months following the last day of the calendar year in which the date of
Executive’s Involuntary Termination occurs: 

  
 5 

 (i)          The Company shall
pay to Executive his or her fully earned but unpaid base salary, when due, through the date of Involuntary Termination at the rate then in effect, plus all other amounts to which Executive is entitled under any compensation plan or practice of the
Company at the time of termination; 
 (ii)          Subject to
Section 5(f) and Executive’s continued compliance with Section 6, Executive shall be entitled to receive severance pay in an amount equal to Executive’s monthly base salary as in effect immediately prior to the date of
Involuntary Termination for the eighteen (18) month period following the date of termination; plus 

(iii)          Subject to Section 5(f) and Executive’s continued
compliance with Section 6, the vesting and/or exercisability of one hundred percent (100%) Executive’s Stock Awards shall be automatically accelerated on the effective date of Executive’s Release. This provision is hereby deemed to be
a part of each Stock Award and to supersede any less favorable provision in any agreement or plan regarding such Stock Award. 

(iv)          The payments and benefits provided for in this
Section 5(b) shall only be payable in the event of Executive’s Involuntary Termination prior to a Change of Control or more than twelve (12) months following a Change of Control. If Executive’s employment is Involuntarily
Terminated within twelve (12) months following a Change of Control, then Executive shall receive the payments and benefits described in Section 5(c) in lieu of the payments and benefits described in this Section 5(b). 

(c)          Severance Upon Involuntary Termination Within 12 Months
Following a Change in Control. If Executive’s employment is Involuntarily Terminated within twelve (12) months following a Change in Control, Executive shall be entitled to receive, in lieu of any severance benefits to which Executive
may otherwise be entitled under any severance plan or program of the Company, the benefits provided below, which, with respect to clause (ii) below, will be payable in a lump sum within ten (10) days following the effective date of
Executive’s Release, but in no event later than two and one-half (2 1/2) months following the last day of the calendar year in which the date of Executive’s Involuntary Termination occurs: 

(i)          The Company shall pay to Executive his or her fully earned but
unpaid base salary, when due, through the date of Involuntary Termination at the rate then in effect, plus all other amounts to which Executive is entitled under any compensation plan or practice of the Company at the time of termination; 

(ii)          Subject to Section 5(f) and Executive’s continued
compliance with Section 6, Executive shall be entitled to receive severance pay in an amount equal to the sum of: 

(A)          Executive’s monthly base salary as in effect immediately
prior to the date of Involuntary Termination for the eighteen (18) month period following the date of termination, plus 

(B)          One and one-half (1
1/2) times Executive’s target bonus for the fiscal year in which the date of Involuntary Termination occurs, with such bonus determined assuming that all of the performances objectives for such fiscal year have been attained; 

  
 6 

 (iii)          Subject to
Section 5(f) and Executive’s continued compliance with Section 6, for the period beginning on the date of Involuntary Termination and ending on the date which is eighteen (18) full months following the date of Involuntary Termination
(or, if earlier, (A) the date on which the applicable continuation period under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) expires or (B) the date Executive
becomes eligible to receive the equivalent or increased healthcare coverage from a subsequent employer) (such period, the “COBRA Coverage Period”) , if Executive and his or her eligible dependents who were
covered under the Company’s health insurance plans as of the date of Executive’s Involuntary Termination elect to have COBRA coverage and are eligible for such coverage, the Company shall reimburse Executive on a monthly basis for an
amount equal to (1) the monthly premium Executive is required to pay for continuation coverage pursuant to COBRA for Executive and his or her eligible dependents who were covered under the Company’s health plans as of the date of
Executive’s Involuntary Termination (calculated by reference to the premium as of the date of Executive’s Involuntary Termination) less (2) the amount Executive would have had to pay to receive group health coverage for Executive and
his or her covered dependents based on the cost sharing levels in effect on the date of Executive’s Involuntary Termination. If any of the Company’s health benefits are self-funded as of the date of Executive’s Involuntary
Termination, or if the Company cannot provide the foregoing benefits in a manner that is exempt from Section 409A (as defined below) or that is otherwise compliant with applicable law (including, without limitation, Section 2716 of the
Public Health Service Act), instead of providing the reimbursements as set forth above, the Company shall instead pay to Executive the foregoing monthly amount as a taxable monthly payment for the COBRA Coverage Period (or any remaining portion
thereof). Executive shall be solely responsible for all matters relating to continuation of coverage pursuant to COBRA, including, without limitation, the election of such coverage and the timely payment of premiums); and 

(iv)          Subject to Section 5(f) and Executive’s continued
compliance with Section 6, the vesting and/or exercisability of any outstanding unvested positions of Executive’s Stock Awards shall be automatically accelerated on the effective date of Executive’s Release. This provision is hereby
deemed to be a part of each Stock Award and to supersede any less favorable provision in any agreement or plan regarding such Stock Award. 

(v)          The payments and benefits provided for in this
Section 5(c) shall only be payable in the event of Executive’s Involuntary Termination within twelve (12) months following a Change of Control. If Executive’s employment is Involuntarily Terminated more than twelve
(12) months following a Change of Control or prior to a Change of Control, then Executive shall receive the payments and benefits described in Section 5(b) and shall not be eligible to receive any of the payments and benefits described in
this Section 5(c) . In addition, if an Executive is not a full-time employee at the time of his or her Involuntary Termination, then Executive shall receive the payments and benefits described in Section 5(b) and shall not be eligible to
receive any of the payments and benefits described in this Section 5(c) as a result of such Involuntary Termination. 

(d)          Other Terminations. If Executive experiences a
Separation from Service by reason of his or her termination of employment by the Company for Cause, by Executive without Good Reason, or as a result of Executive’s death or disability, or in the event the Term expires, the Company shall not
have any other or further obligations to Executive under this Agreement (including any financial obligations) except that Executive shall been entitled to receive (i) Executive’s fully earned but unpaid base salary, through the date of
termination at the rate then in effect, (ii) all other amounts or benefits to which Executive is entitled under any compensation, retirement or benefit plan or practice of the Company at the time of termination in accordance with the terms of
such plans or practices, including, without limitation, any continuation of benefits required by COBRA or applicable law, and (iii) in the event Executive’s employment is terminated as a result of Executive’s death or disability,
Executive shall be entitled to receive a prorated portion of any bonus payment to which Executive was entitled in the year in which such termination occurs, which bonus shall be paid within ten (10) days following the date of termination. 

  
 7 

 In addition, all vesting of Executive’s unvested Stock Awards previously granted to him or
her by the Company shall cease and none of such unvested Stock Awards shall be exercisable following the date of such termination. The foregoing shall be in addition to, and not in lieu of, any and all other rights and remedies which may be
available to the Company under the circumstances, whether at law or in equity. 

(e)          Delay of Payments. Notwithstanding anything to the
contrary in this Section 5, if Executive is a “specified employee” (as defined in Section 409A of the Code), as determined by the Company in accordance with Section 409A of the Code, on the date of Executive’s
Separation from Service, to the extent that the payments or benefits under this Agreement are subject to Section 409A of the Code and the delayed payment or distribution of all or any portion of such amounts to which Executive is entitled under
this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(b)(i) of the Code, then such portion deferred pursuant to this Section 5(e) shall be paid or distributed to Executive in a lump sum on the
earlier of (i) the date that is six (6)-months following Executive’s Separation from Service, (ii) the date of Executive’s death or (iii) the earliest date as is permitted under Section 409A of the Code. Any remaining
payments due under this Agreement shall be paid as otherwise provided herein. 

(f)          Release. As a condition to Executive’s receipt of
any post-termination benefits pursuant to Section 5(b) or 5(c) above, Executive shall execute and not revoke a general release of all claims in favor of the Company (the “Release”) in the form attached
hereto as Exhibit A. In the event Executive does not sign the Release within the fifty (50) day period following the date of Executive’s termination of employment or revokes such Release in accordance with the terms thereof,
Executive shall not be entitled to the aforesaid payments and benefits. 

(g)          Exclusive Remedy. Except as otherwise expressly
required by law (e.g., COBRA) or as specifically provided herein, all of Executive’s rights to salary, severance, benefits, bonuses and other amounts hereunder (if any) accruing after the termination of Executive’s employment shall cease
upon such termination. In the event of a termination of Executive’s employment with the Company, Executive’s sole remedy shall be to receive the payments and benefits described in this Section 5. Any payments made to Executive under this
Section 5 shall be inclusive of any amounts or benefits to which Executive may be entitled pursuant to the WARN Act or the California WARN Act. 

(h)          No Mitigation. Executive shall not be required to
mitigate the amount of any payment provided for in this Section 5 by seeking other employment or otherwise, nor shall the amount of any payment or benefit provided for in this Section 5 be reduced by any compensation earned by Executive as
the result of employment by another employer or self-employment or by retirement benefits; provided, however, that loans, advances or other amounts owed by Executive to the Company may be offset by the Company against amounts payable to
Executive under this Section 5. 
 (i)          Return of the
Company’s Property. If Executive’s employment is terminated for any reason, the Company shall have the right, at its option, to require Executive to vacate his or her offices prior to or on the effective date of termination and to
cease all activities on the Company’s behalf. Upon the termination of his or her employment in any manner, as a condition to Executive’s receipt of any post-termination benefits described in this Agreement, Executive shall immediately
surrender to the Company all lists, books and records of, or in connection with, the Company’s business, and all other property belonging to the Company, it being distinctly understood that all such lists, books and records, and other
documents, are the property of the Company. Executive shall deliver to the Company a signed statement certifying compliance with this Section 5(i) prior to the receipt of any post-termination benefits described in this Agreement. 

  
 8 

 6.          Certain
Covenants. 
 (a)          Noncompetition. Except as may
otherwise be approved by the Board, during the term of Executive’s employment, Executive shall not have any ownership interest (of record or beneficial) in, or have any interest as an employee, salesman, consultant, officer or director in, or
otherwise aid or assist in any manner, any firm, corporation, partnership, proprietorship or other business that engages in any county, city or part thereof in the United States and/or any foreign country in a business which competes directly or
indirectly (as determined by the Board) with the Company’s business in such county, city or part thereof, so long as the Company, or any successor in interest of the Company to the business and goodwill of the Company, remains engaged in such
business in such county, city or part thereof or continues to solicit customers or potential customers therein; provided, however, that Executive may own, directly or indirectly, solely as an investment, securities of any entity which are
traded on any national securities exchange if Executive (x) is not a controlling person of, or a member of a group which controls, such entity; or (y) does not, directly or indirectly, own one percent (1 %) or more of any class of
securities of any such entity. 
 (b)          Employee Proprietary
Information and Inventions Agreement. Executive and the Company have entered into the Company’s standard employee proprietary information and inventions agreement (the “Employee Proprietary Information and Inventions
Agreement”), which agreement is attached hereto as Exhibit B and incorporated herein by reference. Executive agrees to perform each and every obligation of Executive therein contained. 

(c)          Solicitation of Employees. Executive shall not during
the term of Executive’s employment and for one year following Executive’s termination of employment (the “Restricted Period”), directly or indirectly, solicit or
encourage to leave the employment of the Company or any of its affiliates, any employee of the Company or any of its affiliates. 

(d)          Solicitation of Consultants. Executive shall not during
the term of Executive’s employment and for the Restricted Period, directly or indirectly, hire, solicit or encourage to cease work with the Company or any of its affiliates any consultant then under contract with the Company or any of its
affiliates within one year of the termination of such consultant’s engagement by the Company or any of its affiliates. 

(e)          Rights and Remedies Upon Breach. If Executive breaches
or threatens to commit a breach of any of the provisions of this Section 6 (the “Restrictive Covenants”), the Company shall have any rights and remedies available to the Company under law or in equity,
including, without limitation, the right to cease all severance payments and benefits payable pursuant to Section 5 above in the event of Executive’s breach of any of the Restrictive Covenants. 

(f)          Severability of Covenants/Blue Pencilling. If any court
determines that any of the Restrictive Covenants, or any part thereof, is invalid or unenforceable, the remainder of the Restrictive Covenants shall not thereby be affected and shall be given full effect, without regard to the invalid portions. If
any court determines that any of the Restrictive Covenants, or any part thereof, are unenforceable because of the duration of such provision or the area covered thereby, such court shall have the power to reduce the duration or area of such
provision and, in its reduced form, such provision shall then be enforceable and shall be enforced. Executive hereby waives any and all right to attack the validity of the Restrictive Covenants on the grounds of the breadth of their geographic scope
or the length of their term. 

  
 9 

 (g)          Enforceability
in Jurisdictions. The Company and Executive intend to and do hereby confer jurisdiction to enforce the Restrictive Covenants upon the courts of any jurisdiction within the geographical scope of such covenants. If the courts of any one or more of
such jurisdictions hold the Restrictive Covenants wholly unenforceable by reason of the breadth of such scope or otherwise, it is the intention of the Company and Executive that such determination not bar or in any way affect the right of the
Company to the relief provided above in the courts of any other jurisdiction within the geographical scope of such covenants, as to breaches of such covenants in such other respective jurisdictions, such covenants as they relate to each jurisdiction
being, for this purpose, severable into diverse and independent covenants. 

(h)          Definitions. For purposes of this Section 6, the
term “Company” means not only ChemoCentryx, Inc., but also any company, partnership or entity which, directly or indirectly, controls, is controlled by or is under common control with ChemoCentryx, Inc. 

7.          Insurance: Indemnification. 

(a)          Insurance. The Company shall have the right to take out
life, health, accident, “key-man” or other insurance covering Executive, in the name of the Company and at the Company’s expense in any amount deemed appropriate by the Company. Executive shall
assist the Company in obtaining such insurance, including, without limitation, submitting to any required examinations and providing information and data required by insurance companies. 

(b)          Indemnification. Executive will be provided with
indemnification against third party claims related to his or her work for the Company as required by Delaware law. The Company shall provide Executive with directors and officers liability insurance coverage at least as favorable as that which the
Company may maintain from time to time for other members of the Board and executive officers. 

8.          Agreement to Arbitrate. Any dispute, claim or controversy
based on, arising out of or relating to Executive’s employment or this Agreement shall be settled by final and binding arbitration in Santa Clara County, California, before a single neutral arbitrator in accordance with the National Rules for
the Resolution of Employment Disputes (the “Rules” ) of the American Arbitration Association (“AAA”), and judgment on the award rendered by the arbitrator may be entered in
any court having jurisdiction. The Rules may be found online at www.adr.org. Arbitration may be compelled pursuant to the California Arbitration Act (Code of Civil Procedure §§ 1280 et seq.). If the parties are unable to
agree upon an arbitrator, one shall be appointed by the AAA in accordance with its Rules. Each party shall pay the fees of its own attorneys, the expenses of its witnesses and all other expenses connected with presenting its case; provided,
however, Executive and the Company agree that, to the extent permitted by law, the arbitrator may, in his or her discretion, award reasonable attorney’s fees to the prevailing party; provided, however, that the prevailing party shall
be reimbursed for such fees, costs and expenses within forty-five (45) days following any such award, but in no event later than the last day of Executive’s taxable year following the taxable year in which the fees were incurred; provided,
further, that the parties’ obligations pursuant to this sentence shall terminate on the tenth (10th) anniversary of the date of Executive’s termination of employment. Other costs of the
arbitration, including the cost of any record or transcripts of the arbitration, AAA’s administrative fees, the fee of the arbitrator, and all other fees and costs, shall be borne by the Company. This Section 8 is intended to be the
exclusive method for resolving any and all claims by the parties against each other for payment of damages under this Agreement or relating to Executive’s employment; provided, however, that Executive shall retain the right to file
administrative charges with or seek relief through any government agency of competent jurisdiction, and to participate in any government investigation, including but not limited to (a) claims for workers’ compensation, state disability
insurance or unemployment insurance; (b) claims for unpaid wages or waiting time penalties brought before the California Division of Labor Standards Enforcement; provided, however, that any appeal from an award or from denial of an award of
wages and/or waiting time penalties shall be arbitrated pursuant to the terms of this Agreement; and (c) claims for administrative relief from the United States Equal Employment Opportunity Commission and/or the California Department of Fair
Employment and Housing (or any similar agency in any applicable jurisdiction other than California); provided, further, that Executive shall not be entitled to obtain any monetary relief through such agencies other than workers’ compensation
benefits or unemployment insurance benefits. This Agreement shall not limit either party’s right to obtain any provisional remedy, including, without limitation, injunctive or similar relief, from any court of competent jurisdiction as may be
necessary to protect their rights and interests pending the outcome of arbitration, including without limitation injunctive relief, in any court of competent jurisdiction pursuant to California Code of Civil Procedure § 1281.8 or any similar
statute of an applicable jurisdiction. Seeking any such relief shall not be deemed to be a waiver of such party’s right to compel arbitration. Both Executive and the Company expressly waive their right to a jury trial. 

  
 10 

 9.          General
Provisions. 
 (a)          Successors and Assigns. The rights
of the Company under this Agreement may, without the consent of Executive, be assigned by the Company, in its sole and unfettered discretion, to any person, firm, corporation or other business entity which at any time, whether by purchase, merger or
otherwise, directly or indirectly, acquires all or substantially all of the assets or business of the Company. The Company will require any successor (whether direct or indirect, by purchase, merger or otherwise) to all or substantially all of the
business or assets of the Company expressly to assume and to agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place; provided, however,
that no such assumption shall relieve the Company of its obligations hereunder. As used in this Agreement, the “Company” shall mean the Company as hereinbefore defined and any successor to its business
and/or assets as aforesaid which assumes and agrees to perform this Agreement by operation of law or otherwise. Executive shall not be entitled to assign any of Executive’s rights or obligations under this Agreement. This Agreement shall inure
to the benefit of and be enforceable by Executive’s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. 

(b)          Severability. In the event any provision of this
Agreement is found to be unenforceable by an arbitrator or court of competent jurisdiction, such provision shall be deemed modified to the extent necessary to allow enforceability of the provision as so limited, it being intended that the parties
shall receive the benefit contemplated herein to the fullest extent permitted by law. If a deemed modification is not satisfactory in the judgment of such arbitrator or court, the unenforceable provision shall be deemed deleted, and the validity and
enforceability of the remaining provisions shall not be affected thereby. 

(c)          Interpretation; Construction. The headings set forth in
this Agreement are for convenience only and shall not be used in interpreting this Agreement. This Agreement has been drafted by legal counsel representing the Company, but Executive has participated in the negotiation of its terms. Furthermore,
Executive acknowledges that Executive has had an opportunity to review and revise the Agreement and have it reviewed by legal counsel, if desired, and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved
against the drafting party shall not be employed in the interpretation of this Agreement. Either party’s failure to enforce any provision of this Agreement shall not in any way be construed as a waiver of any such provision, or prevent that
party thereafter from enforcing each and every other provision of this Agreement. 

(d)          Governing Law and Venue. This Agreement will be
governed by and construed in accordance with the laws of the United States and the State of California applicable to contracts made and to be performed wholly within such State, and without regard to the conflicts of laws principles thereof. Any
suit brought hereon shall be brought in the state or federal courts sitting in Santa Clara County, California, the Parties hereby waiving any claim or defense that such forum is not convenient or proper. Each party hereby agrees that any such court
shall have in personam jurisdiction over it and consents to service of process in any manner authorized by California law. 

  
 11 

 (e)          Notices.
Any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows with notice deemed given as indicated: (i) by personal delivery when delivered personally; (ii) by overnight courier upon written
verification of receipt; (iii) by telecopy or facsimile transmission upon acknowledgment of receipt of electronic transmission; or (iv) by certified or registered mail, return receipt requested, upon verification of receipt. Notice shall
be sent to Executive at the address listed on the Company’s personnel records and to the Company at its principal place of business, or such other address as either party may specify in writing. 

(f)          Survival. Sections 1 (“Definitions”), 5
(“Termination and Severance”), 6 (“Restrictive Covenants”), 7 (“Insurance and Indemnification”), 8 (“Agreement to Arbitrate”) and 9 (“General Provisions”) of this Agreement shall survive termination
of Executive’s employment by the Company. 
 (g)          Entire
Agreement. This Agreement and the Employee Proprietary Information and Inventions Agreement incorporated herein by reference together constitute the entire agreement between the parties in respect of the subject matter contained herein and
therein and supersede all prior or simultaneous representations, discussions, negotiations, and agreements, whether written or oral. This Agreement may be amended or modified only with the written consent of Executive and an authorized
representative of the Company. No oral waiver, amendment or modification will be effective under any circumstances whatsoever. 

(h)          Code Section 409A. 

(i)          Certain payments and benefits payable under this Agreement are
intended to be exempt from the requirements of Section 409A of the Code. This Agreement shall be interpreted in accordance with the applicable exemptions from Section 409A of the Code. To the extent the payments and benefits under this
Agreement are subject to Section 409A of the Code, this Agreement shall be interpreted, construed and administered in a manner that satisfies the requirements of Sections 409A(a)(2), (3) and (4) of the Code and the Treasury Regulations
thereunder. For purposes of this Agreement, all references to Executive’s “termination of employment” shall mean Executive’s Separation from Service. 

(ii)          To the extent that any reimbursements under this Agreement
are subject to Section 409A, any such reimbursements payable to Executive shall be paid to Executive no later than December 31 of the calendar year following the calendar year in which the expense was incurred; provided that Executive
submits Executive’s reimbursement request promptly following the date the expense is incurred, the amount of expenses reimbursed in one calendar year shall not affect the amount eligible for reimbursement in any subsequent calendar year, and
Executive’s right to reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit. 

(iii)          Executive’s right to receive any installment payments
under this Agreement, including without limitation any continuation salary payments that are payable on Company payroll dates, shall be treated as a right to receive a series of separate payments and, accordingly, each such installment payment shall
at all times be considered a separate and distinct payment as permitted under Section 409A. Except as otherwise permitted under Section 409A, no payment hereunder shall be accelerated or deferred unless such acceleration or deferral would
not result in additional tax or interest pursuant to Section 409A. 

  
 12 

 (iv)          In the event
that the amounts payable under Section 5 are subject to Section 409A of the Code and the timing of the delivery of Executive’s Release could cause such amounts to be paid in one or another taxable year, then notwithstanding the
payment timing set forth in such sections, such amounts shall not be payable until the later of (i) the payment date specified in such section or (ii) the first business day of the taxable year following Executive’s Separation from
Service. 
 (i)          Counterparts. This Agreement may
be executed in multiple counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. 

(Signature Page Follows) 

  
 13 

 THE PARTIES TO THIS AGREEMENT HAVE READ THE FOREGOING AGREEMENT AND FULLY
UNDERSTAND EACH AND EVERY PROVISION CONTAINED HEREIN. WHEREFORE, THE PARTIES HAVE EXECUTED THIS AGREEMENT ON THE DATES SHOWN BELOW. 
  

									
		 		 	 CHEMOCENTRYX, INC.

				
	 Dated: May 2,
2016                                    
	 		 	 By:
	 	 /s/ Thomas J. Schall

		 		 	 Name:
	 	 Thomas J. Schall, Ph.D.

		 		 	 Title:
	 	 President and CEO

			
		 		 	 EXECUTIVE

			
	 Dated: May 2nd,
2016                                  
	 		 	 /s/ Rajinder Singh, D. Phil.

		 		 	 Rajinder Singh, D. Phil.

					
		 		 		 	 Address:
	 	 ****

		 		 		 		 	 ****

  
 14EX-10.14

 Exhibit 10.14 
  

 
 October 11, 2016 

Dr. Jan Hillson 
 **** 

**** 
 Dear Jan: 

It is with great pleasure that I offer you employment at ChemoCentryx, Inc. (“ChemoCentryx” or the
“Company”), on the terms set forth below. As you know, ChemoCentryx is a research-driven drug discovery and development company that is committed to the creation of novel therapeutics for inflammatory diseases and cancer, based on
our specialized and deep expertise of the biology of chemoattractant systems in the body. ChemoCentryx offers a dynamic, vibrant, and progressive research environment with an emphasis on scientific excellence. Our goal, to make fundamental and
meaningful contributions to human health, requires the personal commitment of every employee. 
 If you accept our offer, you will be
employed with the Company as Senior Vice President of Drug Discovery, reporting directly to me, the President and CEO. You will work at our offices in Mountain View, California, subject to any required business travel. 

The Company is prepared to offer a compensation package comprising the following components: 

 

	 	1)	 A base salary at the initial rate of $380,000 per year (i.e., $31,667 per month), less standard payroll
deductions and withholdings, to be paid on the Company’s normal payroll schedule. 

  

	 	2)	 In addition to base salary, you will be eligible to earn an annual bonus of up to 35% of your base salary
based on criteria that include, but are not limited to, the achievement of corporate and personal goals. 

  

	 	3)	 A one-time relocation subsidy of $40,000. 

 

	 	4)	 A monthly transitional housing subsidy of $2500 per month payable for the first 12 months of employment.

  

	 	5)	 An option to purchase 200,000 shares of the Company’s common stock at its fair market value as
determined by the Board as of the date of grant (the “Option”) pursuant to the Company’s 2012 equity incentive plan (the “Plan”). 

You will be eligible to participate in the Company’s standard employee benefits subject to the terms and conditions of the benefit plans
and Company policies, which include the following: major medical, dental and vision insurance coverage; life insurance coverage; short-term and long-term disability insurance 

 Page 2 
  

 
coverage; 40l(k) plan; a Flexible Spending Account option (FSA 125); Employee Stock Purchase Plan; paid holidays; and paid sick leave and vacation accrual. Please note that the long-term
disability insurance coverage is mandatory, employee premiums are required, and the cost of such premiums are included in the base salary amount contained in this letter. Of course, the Company may modify your compensation and benefits from time to
time at its discretion. 
 Some additional details of the components of the CCXI compensation package are as follows. Salary. As an
exempt, salaried employee, you will be required to work the Company’s normal business hours, and additional hours as required by the nature of your work assignments, and you will not be eligible for overtime compensation. Bonus. For
annual bonus, in addition to achievement of corporate and personal goals, in order to be eligible to receive any bonus compensation, employees must receive a satisfactory or better overall rating on their performance evaluation for the bonus year,
and must be employed in good standing (e.g. not subject to verbal counseling, any written warning, or a performance improvement plan) as of the date that the bonuses are paid. The annual bonus is payable at the discretion of the Company, and
the Company will determine whether and to what extent the applicable corporate and personal goals and other bonus criteria have been achieved, and the amount of any earned bonus. You will be eligible for the 2016 bonus year on a pro-rated basis based on your start date. The Option grant will be governed in full by the terms and conditions of the Plan and your individual grant agreement, including the vesting schedule and requirements
set forth therein. All other definitions and terms of your employment will be laid out fully in the Employment Agreement that will be sent to you for your examination, approval and execution after you have reviewed and accepted the general
terms in this Offer Letter. 
 As a condition of your employment, you will be required to abide by the Company’s policies and
procedures, including but not limited to the policies set forth in the Company’s Employee Handbook, as may be in effect from time to time. You will be required to sign an acknowledgement that you have read and will comply with the policies
contained in the Employee Handbook. You also must read, sign and comply with the Company’s Employee Confidential Information and Inventions Assignment Agreement (the “Confidential Information Agreement”), attached hereto as
Exhibit A. 
 In your work for the Company, you are expected not to make unauthorized use or disclosure of any
confidential or proprietary information or materials, including trade secrets, of any former employer or other third party to whom you have an obligation of confidentiality. By signing this letter, you represent that you are able to perform your job
duties within these guidelines, and you are not in unauthorized possession of any confidential documents or other property of any former employer or other third party. You further represent that you have disclosed to the Company in writing any
agreement you may have with any third party (e.g., a former employer) which may conflict with or limit your ability to perform your duties to the Company. 

Although your employment may be for a specified period of time, and may contain termination and severance provisions, it is terminable at
will. This means that you may terminate your employment with the Company at any time and for any reason whatsoever simply by notifying us. Likewise, the Company may terminate your employment at any time, with or without cause, and with or without
advance notice, simply by notifying you. 
 To aid in the rapid and economical resolution of disputes that may arise between us, you and the
Company agree that any and all disputes, claims, or demands in any way arising from or relating to this offer letter agreement, your employment with the Company, or the termination of your employment with the Company, including but not limited to
any statutory claims, shall be resolved, to the fullest extent permitted by law, by final, binding and confidential arbitration in San Francisco, California conducted before a single arbitrator by JAMS, Inc. (“JAMS”) or its
successor, under the then-applicable JAMS rules. You acknowledge that by agreeing to this arbitration procedure, you and the Company waive the right to resolve any such dispute, 

 Page 3 
  

 
claim or demand through a trial by jury or judge or by administrative proceeding. You will have the right to be represented by legal counsel at any arbitration proceeding. The arbitrator shall:
(a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding; and (b) issue a written statement signed by the
arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which the award is based. The Company shall pay all
JAMS’ arbitration fees. Nothing in this offer letter is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any arbitration. 

This letter, your Confidential Information Agreement, and the Employment Agreement form your complete and exclusive agreement with the Company
concerning the subject matter hereof. The employment terms in this letter supersede any other representations or agreements made to you by any party, whether oral or written. The terms of this agreement cannot be changed (except with respect to
those changes expressly reserved to the Company’s discretion in this letter) without a written agreement signed by you and a duly authorized officer of the Company. This agreement is to be governed by the laws of the state of California without
reference to conflicts of law principles. In case any provision contained in this agreement shall, for any reason, be held invalid or unenforceable in any respect, such invalidity or unenforceability shall not affect the other provisions of this
agreement, and such provision will be reformed, construed and enforced so as to render it valid and enforceable consistent with the general intent of the parties insofar as possible under applicable law. With respect to the enforcement of this
agreement, no waiver of any right hereunder shall be effective unless it is in writing. For purposes of construction of this agreement, any ambiguity shall not be construed against either party as the drafter. This agreement may be executed in more
than one counterpart, and signatures transmitted via facsimile or PDF shall be deemed equivalent to originals. 
 As required by law, this
offer is subject to satisfactory proof of your identity and right to work in the United States. We have enclosed the required Federal I-9 Form with a list of acceptable documents for this purpose, so that you
may complete the Form and bring it along with the necessary supporting documents on your first day of work. 
 Your employment at
ChemoCentryx is contingent upon satisfactory completion of professional references and background checks. If you wish to accept employment at ChemoCentryx under the terms contained above, please sign and date this letter and the Confidential
Information Agreement, and return them to me by 5:00 p.m. on Tuesday, October 18, 2016 or sooner. If we do not receive this fully signed letter and signed Confidential Information Agreement from you within this timeframe, the Company’s offer of
employment will expire. 
 We look forward to you joining ChemoCentryx, Jan, and to productive and enjoyable work relationship. 

Very best regards, 
 Thomas J.
Schall, Ph.D. 
 President and Chief Executive Officer 
  

 

							
	 Understood and Accepted:
	 		 		 	
				
	 /s/ Jan Hillson
	 		 	 17 Oct 2016
	 	
	Jan Hillson, MD	 		 	Date	 	

 EXHIBITA 

EMPLOYEE CONFIDENTIAL INFORMATION AND INVENTIONS ASSIGNMENT AGREEMENT 

  
 A-1 

 EMPLOYEE CONFIDENTIAL INFORMATION AND INVENTIONS ASSIGNMENT AGREEMENT 

In consideration of my employment or continued employment by ChemoCentryx, Inc or its subsidiaries or affiliates (the
“Company”), and the compensation paid to me now and during my employment with the Company, I agree to the terms of this Agreement as follows: 

 

 CONFIDENTIAL INFORMATION PROTECTIONS. 

Nondisclosure; Recognition of Company’s Rights. At all times during and after my employment, I will hold in confidence and will not
disclose, use, lecture upon, or publish any of Company’s Confidential Information (defined below), except as may be required in connection with my work for Company, or as expressly authorized in writing by an officer of Company. I will obtain
such officer’s written approval before publishing or submitting for publication any material (written, oral, or otherwise) that relates to my work at Company and/or incorporates any Confidential Information. I hereby assign to Company any
rights I have or may acquire in any and all Confidential Information and recognize that all Confidential Information shall be the sole and exclusive property of Company and its assigns. 

Confidential Information. The term “Confidential Information” shall mean any and all confidential knowledge, data or
information related to Company’s business or its actual or demonstrably anticipated research or development, including without limitation (a) trade secrets, inventions, ideas, processes, computer source and object code, data, formulae,
programs, other works of authorship, know-how, improvements, discoveries, developments, designs, techniques, methodologies, techniques, processes, assay systems, procedures, tests, formulations, gene sequences
and loci, compounds, micro-organisms or other cell types, proteins, peptides, genetic and other biological material, computer programs, algorithms, software, reports, documentation, equipment, and devices; (b) information regarding products,
services, plans for research and development, unpublished test results, clinical trials, marketing and business plans, budgets, financial statements, contracts, prices, suppliers, and customers; (c) information regarding the skills and
compensation of Company’s employees, contractors, and any other service providers of Company; and (d) the existence of any business discussions, negotiations, or agreements between Company and any third party. 

Third Party Information. I understand that Company has received and in the future will receive from third parties confidential or proprietary
information (“Third Party Information”) subject to a duty on Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. During and after the term of my employment, I will
hold Third Party Information in strict confidence and will not disclose to anyone (other than Company personnel who need to

 
know such information in connection with their work for Company) or use, Third Party Information, except in connection with my work for Company or unless expressly authorized by an officer
of Company in writing. 
 No Improper Use of Information of Prior Employers and Others. I represent that my employment by Company does not
and will not breach any agreement with any former employer, including any noncompete agreement or any agreement to keep in confidence or refrain from using information acquired by me in confidence or trust prior to my employment by Company. I
further represent that I have not entered into, and will not enter into, any agreement, either written or oral, in conflict with my obligations under this Agreement. During my employment by Company, I will not improperly use or disclose any
confidential information or trade secrets of any former employer or other third party, nor will I bring onto the premises of Company or use any unpublished documents or any property belonging to any former employer or other third party, in violation
of any lawful agreements with that former employer or third party. I will use in the performance of my duties only information that is generally known and used by persons with training and experience comparable to my own, is common knowledge in the
industry or otherwise legally in the public domain, or is otherwise provided or developed by Company. 
 INVENTIONS. 

Inventions and Intellectual Property Rights. As used in this Agreement, the term “Invention” means any ideas, concepts,
information, materials, processes, methods, data, programs, know-how, improvements, discoveries, developments, designs, artwork, formulae, other patentable or copyrightable works, and techniques and all
Intellectual Property Rights in any of the items listed above. The term “Intellectual Property Rights” means all trade secrets, copyrights, trademarks, mask work rights, patents and other intellectual property rights recognized by
the laws of any jurisdiction or country. 
 Prior Inventions. I have disclosed on Exhibit A a complete list of all Inventions that
(a) I have, or I have caused to be, alone or jointly with others, conceived, developed, or reduced to practice prior to the commencement of my employment by Company; (b) in which I have an ownership interest or which I have a license to
use; and (c) I wish to have excluded from the scope of this Agreement (collectively referred to as “Prior Inventions”). If no Prior Inventions are listed in Exhibit A,

 

  
 1 

 
I warrant that there are no Prior Inventions. I agree that I will not incorporate, or permit to be incorporated, Prior Inventions in any Company Inventions (defined below) without Company’s
prior written consent. If, in the course of my employment with Company, I incorporate a Prior Invention into a Company process, machine or other work, I hereby grant Company a non-exclusive, perpetual,
fully-paid and royalty-free, irrevocable and worldwide license, with rights to sublicense through multiple levels of sublicensees, to reproduce, make derivative works of, distribute, publicly perform, and publicly display in any form or medium,
whether now known or later developed, make, have made, use, sell, import, offer for sale, and exercise any and all present or future rights in, such Prior Invention. 

Assignment of Company Inventions. Inventions assigned to the Company or to a third party as directed by the Company pursuant to the section
titled “Government or Third Party” are referred to in this Agreement as “Company Inventions.” Subject to the section titled “Government or Third Party” and except for Inventions that I can prove qualify fully
under the provisions of California Labor Code section 2870 and that I have set forth in Exhibit A, I hereby assign and agree to assign in the future (when any such Inventions or Intellectual Property Rights are first reduced to practice or
first fixed in a tangible medium, as applicable) to Company all my right, title, and interest in and to any and all Inventions (and all Intellectual Property Rights with respect thereto) made, conceived, reduced to practice, or learned by me, either
alone or with others, during the period of my employment by Company. 
 Obligation to Keep Company Informed. During the period of my
employment and for one (1) year after my employment ends, I will promptly and fully disclose to Company in writing (a) all Inventions authored, conceived, or reduced to practice by me, either alone or with others, including any that might
be covered under California Labor Code section 2870, and (b) all patent applications filed by me or in which I am named as an inventor or co-inventor. 

Government or Third Party. I agree that, as directed by the Company, I will assign to a third party, including without limitation the United
States, all my right, title, and interest in and to any particular Company Invention. 
 Enforcement of Intellectual Property Rights and
Assistance. During and after the period of my employment, I will assist Company in every proper way to obtain and enforce United States and foreign Intellectual Property Rights relating to Company Inventions in all countries. If the Company is
unable to secure my signature on any document needed in connection with such purposes, I hereby irrevocably designate and appoint Company and its duly authorized officers and

 
agents as my agent and attorney in fact, which appointment is coupled with an interest, to act on my behalf to execute and file any such documents and to do all other lawfully permitted acts to
further such purposes with the same legal force and effect as if executed by me. 
 Incorporation of Software Code. I agree that I will not
incorporate into any Company software or otherwise deliver to Company any software code licensed under the GNU General Public License or Lesser General Public License or any other license that, by its terms, requires or conditions the use or
distribution of such code on the disclosure, licensing, or distribution of any source code owned or licensed by Company. 
 RECORDS. I agree to
keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that is required by the Company) of all Inventions made by me during the period of my employment by the Company, which records shall be
available to, and remain the sole property of, the Company at all times. 
 ADDITIONAL ACTIVITIES. I agree that
during the term of my employment by Company, I will not, without the Company’s express written consent, engage in any employment or business activity directly related to or competitive with the business in which the Company is now or becomes
involved, or would otherwise conflict with my obligations to the Company. To protect the Company’s Intellectual Property Rights, and because of the position in the Company that I hold, I agree that during my employment with the Company whether
full-time or part-time and for a period of one year after my last day of employment with the Company, I will not directly or indirectly, solicit, induce or encourage, or attempt to solicit, induce, or encourage or otherwise cause any employee,
consultant or independent contractor of the Company to terminate his or her relationship with the Company in order to become an employee, independent contractor, or consultant to or for any other person or entity. 

RETURN OF COMPANY PROPERTY. Upon termination of my employment or upon Company’s
request at any other time, I will deliver to Company all of Company’s property, equipment, and documents, together with all copies thereof, and any other material containing or disclosing any Inventions, Third Party Information or Confidential
Information and certify in writing that I have fully complied with the foregoing obligation. I agree that I will not copy, delete, or alter any information contained upon my Company computer or Company equipment before I return it to Company. In
addition, if I have used any personal computer, server, or e-mail system to receive, store, review, prepare or transmit any Company information, including but not limited to, Confidential Information, I agree
to provide the Company with a computer-useable copy of all such Confidential 

 

  
 2 

 
Information and then permanently delete and expunge such Confidential Information from those systems; and I agree to provide the Company access to my system as reasonably requested to verify that
the necessary copying and/or deletion is completed. I further agree that any property situated on Company’s premises and owned by Company is subject to inspection by Company’s personnel at any time with or without further notice. Prior to
the termination of my employment or promptly after termination of my employment, I will cooperate with Company in attending an exit interview and certify in writing that I have complied with the requirements of this section. 

NOTIFICATION OF NEW EMPLOYER. In the event that I leave the employ of Company, I
hereby consent to the notification of my new employer of my rights and obligations under this Agreement, by Company providing a copy of this Agreement or otherwise.

 

  
 3 

 GENERAL PROVISIONS. 

Governing Law and Venue. This Agreement and any action related thereto will be governed, controlled, interpreted and defined by and under the
laws of the State of California, without giving effect to any conflicts of laws principles that require the application of the law of a different state. I hereby expressly consent to the personal jurisdiction and venue in the state and federal
courts for the county in which Company’s principal place of business is located for any lawsuit filed there against me by Company arising from or related to this Agreement. 

Severability. If any provision of this Agreement is, for any reason, held to be invalid or unenforceable, the other provisions of this
Agreement will be unimpaired and the invalid or unenforceable provision will be deemed modified so that it is valid and enforceable to the maximum extent permitted by law. 

Survival. This Agreement shall survive the termination of my employment and the assignment of this Agreement by Company to any successor-in-interest or other assignee and be binding upon my heirs and legal representatives. 

Employment. I agree and understand that nothing in this Agreement shall give me any right to continued employment by Company, and it will not
interfere in any way with my right or Company’s right to terminate my employment at any time, with or without cause and with or without advance notice. 

Notices. Each party must deliver all notices or other communications required or permitted under this Agreement in writing to the other party
at the address listed on the signature page, by courier, by certified or registered mail (postage prepaid and return receipt requested), or by a nationally-recognized express mail service. Notice will be effective upon receipt or refusal of
delivery. If delivered by certified or registered mail, notice will be considered to have been given five (5) business days after it was mailed, as evidenced by the postmark. If delivered by courier or express mail service, notice will be
considered to have been given on the delivery date reflected by the courier or express mail service receipt. Each party may change its address for receipt of notice by giving notice of such change to the other party.

 Injunctive Relief. I acknowledge that, because my services are personal and unique and because I
will have access to the Confidential Information of Company, any breach of this Agreement by me would cause irreparable injury to Company for which monetary damages would not be an adequate remedy and, therefore, will entitle Company to injunctive
relief (including specific performance). The rights and remedies provided to each party in this Agreement are cumulative and in addition to any other rights and remedies available to such party at law or in equity. 

Waiver. Any waiver or failure to enforce any provision of this Agreement on one occasion will not be deemed a waiver of any other provision or
of such provision on any other occasion. 
 Export. I agree not to export, directly or indirectly, any U.S. technical data acquired from
Company or any products utilizing such data, to countries outside the United States, because such export could be in violation of the United States export laws or regulations. 

Entire Agreement. The obligations pursuant to sections of this Agreement titled “Confidential Information Protections” and
“Inventions” shall apply at any time during which I was previously employed, or am in the future employed by Company or, to the fullest extent permitted by law, to any time during which I was previously engaged, or am in the future
engaged, by Company as an independent contractor, if no other agreement governs nondisclosure and assignment of inventions during such period. This Agreement is the final, complete and exclusive agreement of the parties with respect to the subject
matter hereof and supersedes and merges all prior communications between us with respect to such matters. No modification of or amendment to this Agreement, or any waiver of any rights under this Agreement, will be effective unless in writing and
signed by me and an officer of the Company. Any subsequent change or changes in my duties, salary or compensation will not affect the validity or scope of this Agreement.

 

  
 (Signatures on the
following page) 

  
 4 

 This Agreement shall be effective as of the first day of my employment with Company. 

 

					
	EMPLOYEE:	 		 	CHEMOCENTRYX, INC.:
			
	I HAVE READ, UNDERSTAND, AND ACCEPT THIS AGREEMENT AND HAVE BEEN GIVEN THE OPPORTUNITY TO DISCUSS IT WITH INDEPENDENT LEGAL COUNSEL	 		 	ACCEPTED AND AGREED:
	 /s/ Jan Hillson

(Signature)
	 		 	  

(Signature)

			
	 By:
 Jan Hillson,
MD
	 		 	 By:

     

			
	 Title:

     
	 		 	 Title:

     

			
	 Date:
 16 Oct
2016
	 		 	 Date:

     

			
	 Address:
 ****

****
	 		 	 Address:
     

    

  
 5 

 EXHIBIT A 

INVENTIONS 
 1.
        Prior Inventions Disclosure. The following is a complete list of all Prior Inventions (as provided in Section 2.2 of the attached Employee Confidential Information and Inventions Assignment
Agreement, defined herein as the “Agreement”): 
  

					
		 	☒	  	  None
			
		 	☐	  	  See immediately below:
		
		 	  

		
		 	  

			
		 	☐	  	  Additional sheets attached.

 2.         Due to a prior confidentiality agreement, I cannot complete the disclosure
under Section 1 above with respect to inventions or improvements generally listed below and the proprietary rights and obligations with respect to which I owe to the following party(ies): 

 

							
		  	Invention or Improvement        	  	Party(ies)	  	Relationship
				
	 1.        
	  	 
        
	  	  
	  	  

				
	 2.
	  	          
	  	  
	  	  

				
	 3.
	  	          
	  	  
	  	  

				
		  	☐         Additional sheets attached.	  		  	

 3.         Limited Exclusion Notification. 

THIS IS TO NOTIFY you in accordance with Section 2872 of the California Labor Code that the foregoing Agreement between you and
Company does not require you to assign or offer to assign to Company any Invention that you develop entirely on your own time without using Company’s equipment, supplies, facilities or trade secret information, except for those Inventions that
either: 
 a.         Relate at the time of conception or reduction to practice to Company’s
business, or actual or demonstrably anticipated research or development; or 
 b.         Result
from any work performed by you for Company. 
 To the extent a provision in the foregoing Agreement purports to require you to assign an
Invention otherwise excluded from the preceding paragraph, the provision is against the public policy of this state and is unenforceable. 

This limited exclusion does not apply to any patent or Invention covered by a contract between Company and the United States or any of its
agencies requiring full title to such patent or Invention to be in the United States.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}]]